Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

Phase 2/3 Unknown 64 enrolled Tang-Du Hospital

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of tocilizumab in the treatment of generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study tMG(NCT05067348).

Timeline

Start: 2023-04-01
Primary completion: 2024-07-31
Completion: 2024-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tocilizumab	Monoclonal antibody	8 mg/kg	Intravenous

Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

Summary

Timeline

Drugs

Indications